Table 1 Summary of somatic copy number aberrations showing a difference in frequency between pure-cLCIS, inv-cLCIS and cILC
From: PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression
Chr | Region | Genes | Type of SCNA | PURE c-LCIS (27) | INV-cLCIS (28) | cILC (25) | P_values | ||
|---|---|---|---|---|---|---|---|---|---|
| Â | Pure cLCIS vs INV-cLCIS | INV-cLCIS vs cILC | Across all 3 groups | ||||||
5 | 39436375-39620648 (p13.1) | LOC101926940 | Gain | 4 | 0 | 3 | 0.05 | 0.1 | 0.1 |
5 | 129741359-131422972 (q23.3 – q31.1) | HINT1, LYRM7, CDC42SE2, RAPGEF6, FNIP1,MEIKIN, ACSL6, IL3, CSF2 | Gain | 4 | 0 | 2 | 0.05 | 0.2 | 0.09 |
6 | 82391438-171115067 (q14.1 – q27) | Many including: MAP3K7, FOXO3, ESR1, IGF2R, MAP3K4, etc. | Loss | 0 | 2 | 10 | 0.5 | 0.007 | 0.00007 |
8 | 5412833-8927086 (p23.2-p23.1) | MCPH1, ANGPT2, AGPAT5, XKR5, Defensins, FAM66B,SPAG11B &A,CLDN23, ERI1 | Loss | 1 | 2 | 9 | 1 | 0.04 | 0.002 |
10 | 75541103-76515425 (q22.2) | CHCHD1,VCL,PLAU,ADK,AP3M1, CAMK2G, NDST2 | Gain | 2 | 0 | 5 | 0.2 | 0.05 | 0.03 |
11 | 68961001-71551048 (q13.3 – q13.4) | CCND1, MYEOV, FGF4, FGF3 | Gain (Amp) | 0 | 4 (2) | 6 (5) | 0.1 | 0.1 | 0.02 |
17 | 29779560-29899917 (q11.2) | RAB11FIP4 | Gain (Amp) | 5 (1) | 0 | 0 | 0.02 | 0.005 | 0.005 |
18 | 727180-742194 (p11.32) | YES1 | Gain (Amp) | 7 (1) | 2 | 0 | 0.07 | 0.02 | 0.02 |
X | 55670623-57693679 (p11.21) | KLF8 | Gain | 10 | 0 | 1 | 0.0003 | 0.00004 | 0.00004 |
20 | 14695735-15225214 (p12.1) | MACROD2 | Gain | 6 | 0 | 1 | 0.01 | 0.006 | 0.006 |
22 | 47751337-51304566 (q13.31 - q13.3) | BRD1, HDAC10, MAPK12. MAPK11 …. | Loss | 2 | 4 | 13 | 0.6 | 0.005 | 0.0003 |